Publicação científica trimestral do CREMERJ - volume 2 - número 1 - 2023

40 Manejo das complicações gastroenterológicas no paciente diabético José Galvão-Alves e Bruna Cerbino de Souza Med. Ciên. e Arte , Rio de Janeiro, v.2, n.1, p.16-41, jan-mar 2023 26. Afghani E, Sinha A, Singh VK. An overview of the diagnosis and management of nutrition in chronic pancreatitis. Nutr Clin Pract 2014; 29:295-311. 27. Gheorghe C, Seicean A, Saftoiu A, Tantau M, Dumitru E, Jinga M, Negreanu L, Mateescu B, Gheorghe L, Ciocirlan M, Cijevschi C, Constantinescu G, Dima S, Diculescu M. (2015) Romanian guidelines on the diagnosis and treatment of exocrine pancreatic insufficiency. J Gastrointestin Liver Dis. Mar;24(1):117-23. 28. Holst JJ et al. (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med.Res.Opin. 27, 547-558. 29. Latorre R et al. (2016) Enteroendocrine cells: a review of their roleinbrain-out communication. Neurogastroenterol. Motil. 28, 620-630. 30. Mawe GM and Hoffman JM (2013). Serotonin signalling in the gut–functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 10, 473-486. 31. Vaarala O et al. (2008) The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57, 2555-2562. 32. Domenech A et al. (2011) Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/ hIFNbetatransgenicmice. Int. J.Exp.Pathol. 92, 400-412. 33. Itoh H et al. (2004) Regeneration of injured intestinal mucosais impaired in hepatocyte growth factor activator-deficient mice. Gastroenterology 127, 1423-1435. 34. Wang CL et al. (2013) In vivo characterization of intestinal effects of endomorphin-1 and endomorphin-2 in type 1 diabetic mice. Eur. J.Pharmacol. 698, 499-504. 35- Rana S, Malik A, Bhadada SK, Sachdeva N, Morya RK, Sharma G. Malabsorption, orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetic patients: a connection. Indian J Clin Biochem 2017;32(1):84-89. 36. D'Addio F, Fiorina P. Type 1 Diabetes and Dysfunctional Intestinal Homeostasis. Trends Endocrinol Metab. 2016 Jul;27(7):493-503. 37. Adamska A, Nowak M, Pilacinski S, et al. Small intestinal bacterial overgrowth in adult patients with type 1 diabetes: its prevalence and relationship with metabolic control and the presence of chronic complications of the disease. Pol Arch Med Wewn. 2016;126(9):628-34. 38. McQuaid, Kenneth R. Chapter 15 – Gastrointestinal Disorders In: Michael W. Rabow, Stephen J.McPhee, Maxine A.Papadakis, Current - Medical Diagnosis e Treatment, 57ª edição, Lange Medical Books/ McGraw-Hill, 2018. 39. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793-801. 40. Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612. 41. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-1747. 42. Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649. 43. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589. 44. Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21: 191-198.